PIK3CA and cervical cancer: As a result, detailed analyses of the TME in these trials are required to explain the role of PI3K class I isoforms in the function of different cell types and to ensure that PI3K inhibitors may be used as a highly active, safe, and tolerated therapy option in cervical cancers.